Anbio Biotechnology

Anbio Biotechnology (NNNN) priced its initial public offering on Feb 19, 2025 at $5.00 per share, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $219.5M. AC Sunshine was lead-left underwriter. Ortoli Rosenstadt and Mourant advised the company.

Anbio Biotechnology develops and provides in vitro diagnostics (IVD) products for over-the-counter, point-of-care and laboratory use. Its tests detect biomarkers related to infectious diseases, cancer, cardiovascular disease, inflammation, drug abuse, endocrine disorders, renal disease and diabetes.

Status

IPO

Ticker

NNNN

Exchange

Nasdaq Global Market

Priced

Feb 19, 2025

IPO price

$5.00

Market cap at IPO price

$219.5M

First filed

Dec 31, 2024

Underwriters

AC Sunshine

Company counsel

Ortoli Rosenstadt and Mourant

Sector

Biotech & pharma

Country / state

Germany

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.